By JULIE CUNNINGHAM
(National) A beacon of hope is shining on the second COVID-19 outbreak in the United States and over the world. A second US company has come forward with positive results regarding their COVID-19 vaccine trials. Moderna has released interim findings from stage three human trials that suggest the vaccine is 94.5% effective in preventing the virus. COVID-19 vaccines could be available as early as December according to some reports. Moderna’s vaccine can be stored at normal refrigerated temperatures making it easier to distribute than Pfizer’s vaccine. Pfizer announced early last week their vaccine is reportedly 90% effective, but most be stored at temperatures far below normal, at about -70 degrees Celsius.